HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.

10th Edition of International Conference on Neurology and Brain Disorders

October 21-23, 2024

October 21 -23, 2024 | Baltimore, Maryland, USA
INBC 2024

Jag H Khalsa

Speaker at Brain Disorders Conference - Jag H Khalsa
GWU School of Medicine and Health Sciences, United States
Title : Cannabis/CBD for treating neurological disorders


Cannabis is the most used illegal drug in the world with an estimated 2.5% of the world’s population (180 million) using it regularly (World Drug Report 2017)1. Medicinal and/or recreational cannabis use is associated with significant health consequences) (WHO, 20162; Volkow et al.3), and cannabis use as medicine remains the subject of extensive reviews and debates around the globe. There is paucity of clinical evidence from placebo controlled, double-blind randomized clinical trials that would support the approval of the cannabis plant, whether smoked or as an extract as medicine by the FDA or other regulatory agency in any country. FDA has approved three cannabis compounds: (i) synthetic THC (dronabinol, Marinol) for treating chemotherapy-associated nausea & vomiting; (ii) a synthetic cannabinoid like THC (nabilone, Cesamet) to stimulate appetite in AIDS-wasting and for treating chemotherapy associated nausea and vomiting; and (iii) CBD (Epidiolex) for treating two rare conditions of epilepsy (LG-Dravet syndromes) in young children and a rare benign brain tumor. A combination of CBD and THC (nabiximols, Sativex) is approved for treating neuropathic pain in 20+ countries (but not in the USA). Neither FDA nor any other regulatory agency has approved cannabis, THC, CBD, nor any of the 125 identified cannabinoids for treating a wide range clinical indications including neurological disorders being promoted (Khalsa et al., 2018,3 Khalsa et al. 20234). The National Academy of Sciences (2017)5 and others recommend that additional research be conducted before any cannabinoid, but not smoked cannabis, can be used to treat any neurological disorder. This presentation will further show if current clinical evidence is adequate to support the use of cannabis, CBD, or any other cannabinoid to treat many clinical conditions including neurological disorders being promoted. If time permits, Dr. Khalsa will also discuss the various mechanisms of funding at NIH.


Jag H. Khalsa, MS, PhD, DFISAM, currently is serving as a Special Volunteer/Guest Researcher at National Institute on Drug Abuse, NIH; retired on October 2017 after 40 years of US Federal service (10 at FDA and 30 years at NIH) as the Chief, Medical Consequences of Drug Abuse and Infections Branch, NIDA, NIH), Adjunct Prof, GWU School of Medicine & Health Sciences, and Institute of Human Virology, UM School of Medicine. He is a recipient of numerous Lifetime Achievement awards in Addiction Science and Addiction Medicine, including Distinguished Fellow of the International Society of Addiction Medicine (DFISAM), and serves on several editorial boards including the Journal of Addiction Medicine.